摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-氟苯基)哌嗪盐酸盐 | 64090-19-3

中文名称
1-(4-氟苯基)哌嗪盐酸盐
中文别名
1-(4-氟苯基)哌嗪二盐酸盐
英文名称
1-(4-Fluorophenyl)piperazine dihydrochloride
英文别名
1-(4-fluorophenyl)piperazine;dihydrochloride
1-(4-氟苯基)哌嗪盐酸盐化学式
CAS
64090-19-3
化学式
C10H15Cl2FN2
mdl
——
分子量
253.14
InChiKey
DZQVAQAZQDURKX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    231-234 °C(lit.)
  • 溶解度:
    DMSO:10mg/mL; PBS(pH 7.2):10 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    -7.07
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    21
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险等级:
    6.1
  • 安全说明:
    S22,S26,S36/37/39,S45
  • 危险品运输编号:
    UN 2811 6.1/PG 2
  • WGK Germany:
    3
  • 海关编码:
    2933599090
  • 危险类别:
    6.1
  • 危险品标志:
    T
  • 危险类别码:
    R23/24/25,R36/37/38
  • 包装等级:
    II

SDS

SDS:de7d9870661b0d56e6fb4efc34ab5fb0
查看

反应信息

  • 作为反应物:
    描述:
    1-(4-氟苯基)哌嗪盐酸盐N-{[4-(1-chloroethyl)phenyl]methyl}acetamide 以the title compound was obtained as white crystals, m.p.=128-130° C.的产率得到N-(4-(1-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)phenylmethyl)-acetamide
    参考文献:
    名称:
    Piperazine compounds and medicinal use thereof
    摘要:
    本发明涉及一种哌嗪化合物,其化学式为1,其中R1和R2分别为氢、卤素、低碳基、低碳氧基、氨基、取代氨基、硝基、羟基或氰基,R3、R4和R5分别为氢、卤素、低碳基、低碳氧基、硝基、氨基、取代氨基或羟基,R6和R7分别为氢、低碳基、被卤素取代的低碳基、芳基烷基、酰基或被卤素取代的低酰基,R1和R9分别为氢或低碳基,Y为低碳基亚烷基等,环A为苯基、嘧啶基、噻唑基、吡啶基、吡唑基或咪唑基,以及含有这些化合物的药学制剂。本发明化合物具有优异的TNF-α产生抑制作用和/或IL-10产生促进作用,而且由于它不含或仅表现出对中枢神经系统的作用明显降低,因此该化合物可用作高度安全和优异的TNF-α产生抑制剂和/或IL-10产生促进剂,并可用作预防或治疗由异常TNF-α产生引起的各种疾病,可用于治疗可通过IL-10治愈的疾病,例如慢性炎症性疾病、急性炎症性疾病、感染引起的炎症性疾病、自身免疫性疾病、过敏性疾病和TNF-α介导的疾病。
    公开号:
    US20030055064A1
点击查看最新优质反应信息

文献信息

  • [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
    申请人:CHONG KUN DANG PHARMACEUTICAL CORP
    公开号:WO2017018803A1
    公开(公告)日:2017-02-02
    The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.
    本发明涉及具有组蛋白去乙酰化酶6(HDAC6)抑制活性的新化合物,其立体异构体或药学上可接受的盐,其用于制备治疗药物,含有相同化合物的药物组合物,使用该组合物治疗疾病的方法,以及制备新化合物的方法。根据本发明,这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶(HDAC)抑制活性,并且对于预防或治疗HDAC6介导的疾病有效。
  • [EN] N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF<br/>[FR] DERIVES N-HYDROXYAMIDE ET LEUR APPLICATION
    申请人:APPLIED RESEARCH SYSTEMS
    公开号:WO2006010751A1
    公开(公告)日:2006-02-02
    The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
    本发明涉及式(I)的N-羟基酰胺衍生物及其用途,特别是用于治疗和/或预防自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、癌症、呼吸道疾病和纤维化,包括多发性硬化症、关节炎、肺气肿、慢性阻塞性肺病、肝脏和肺部纤维化。
  • Imidazopyrimidine derivatives and triazolopyrimidine derivatives
    申请人:——
    公开号:US20040054179A1
    公开(公告)日:2004-03-18
    A compound of the formula (I) wherein R 1 is —X—R 4 , an optionally substituted heterocyclic residue, an optionally substituted carbocyclic residue or optionally substituted condensed ring moiety; X is CR 5 R 6 , O, S, SO, SO 2 or NR 7 ; Y is CH or N; R 2 is H, an optionally substituted C 1 -C 10 alkyl,etc.; R 3 is an optionally substituted aryl, or an optionally substituted heteroaryl, etc.; R 4 is an optionally substituted aryl, an optionally substituted heteroaryl, etc.; R 5 , R 6 , and R 7 can be identical or different and represent H, an optionally substituted C 1 -C 10 alkyl, etc. The compound has an excellent anti-allergic activity and the like. 1
    化合物的结构式(I),其中R1是—X—R4,可选择取代的杂环残基,可选择取代的碳环残基或可选择取代的紧缩环基;X是CR5R6,O,S,SO,SO2或NR7;Y是CH或N;R2是H,可选择取代的C1-C10烷基等;R3是可选择取代的芳基,或可选择取代的杂芳基等;R4是可选择取代的芳基,可选择取代的杂芳基等;R5、R6和R7可以相同也可以不同,代表H,可选择取代的C1-C10烷基等。该化合物具有出色的抗过敏活性等。
  • [EN] IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES<br/>[FR] DERIVES IMIDAZOPYRIMIDINE ET TRIAZOLOPYRIMIDINE
    申请人:BAYER AG
    公开号:WO2001083485A1
    公开(公告)日:2001-11-08
    A compound of the formula (I) wherein R1 is -X-R4, an optionally substituted heterocyclic residue, an optionally substituted carbocyclic residue or optionally substituted condensed ring moiety; X is CR5R6, O, S, SO, SO¿2? or NR?7¿; Y is CH or N; R2 is H, an optionally substituted C¿1?-C10 alkyl,etc.; R?3¿ is an optionally substituted aryl, or an optionally substituted heteroaryl, etc.; R4 is an optionally substituted aryl, an optionally substituted heteroaryl, etc.; R?5, R6, and R7¿ can be identical or different and represent H, an optionally substituted C¿1?-C10 alkyl, etc. The compound has an excellent anti-allergic activity and the like.
    化合物的化学式为(I),其中R1为-X-R4,可选取代的杂环残基、可选取代的碳环残基或可选取代的缩合环基;X为CR5R6,O,S,SO,SO2或NR7;Y为CH或N;R2为H,可选取代的C1-C10烷基等;R3为可选取代的芳基或可选取代的杂芳基等;R4为可选取代的芳基或可选取代的杂芳基等;R5,R6和R7可以相同或不同,表示H,可选取代的C1-C10烷基等。该化合物具有优异的抗过敏活性等。
  • Piperazino methyl phenyl aminoquinolines
    申请人:The Upjohn Company
    公开号:US04140775A1
    公开(公告)日:1979-02-20
    Antihypertensive compounds of the formula III ##STR1## wherein X is chloro or trifluoromethyl; wherein R is hydrogen or alkyl of 1 to 3 carbon atoms, inclusive; wherein R.sub.1 is phenyl or phenyl substituted with one or two alkyl, alkoxy, trifluoromethyl or halo substituents, in which alkyl and alkoxy are each of 1 to 3 carbon atoms, inclusive, and halo is fluoro, chloro or bromo, are prepared by reacting a 4-chloro-7-substituted quinoline of formula I with a compound of the formula II ##STR2## wherein R and R.sub.1 are defined as above. The pharmacologically acceptable acid addition salts of compounds of formula III can also be used as antihypertensive agents.
    公式III的降压化合物为##STR1## 其中X为氯或三氟甲基;其中R为氢或1至3个碳原子的烷基;其中R.sub.1为苯基或被一或两个烷基,烷氧基,三氟甲基或卤素取代的苯基,其中烷基和烷氧基均为1至3个碳原子,卤素为氟,氯或溴。所述化合物通过将公式I的4-氯-7-取代喹啉与公式II的化合物反应而制备。公式III化合物的药学上可接受的酸盐也可用作降压剂。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
hnmr
mass
cnmr
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台